AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8749149
Drug: Clemastine 2
RxNorm normalized name: clemastine 2 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine 2 mg twice daily
Trial: 7848623
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug therapy (one of five active drugs)
Trial: 7848623
Drug: Nutritional‐hygienic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional‐hygienic therapy and active drugs
Trial: 2595644
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous PK 11195
Trial: 4590668
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate aerosol at a dosage of 400 to 800 mug/day for three months
Trial: 4590668
Drug: Steroid aerosols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid aerosols (betamethasone valerate or beclomethasone dipropionate) at a daily maintenance dose of 200 mug/day
Trial: 4590668
Drug: Steroid aerosols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid aerosols (betamethasone valerate or beclomethasone dipropionate)
Trial: 25683592
Drug: Prednisolone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (0.5 mg kg(-1) daily)
Trial: 23533302
Drug: Aged garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract (AGE) 1.2 g/day for 12 weeks
Trial: 22134936
Drug: video capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: video capsule endoscopy (VCE)
Trial: 16798758
Drug: Ramp ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramp ATP therapy
Trial: 16627459
Drug: Burst+ ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burst+ ATP therapy
Trial: 9048271
Drug: Delayed-release oral
RxNorm normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release oral azathioprine 200 mg
Trial: 9048271
Drug: Delayed-release oral
RxNorm normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release oral azathioprine 400 mg
Trial: 9048271
Drug: Delayed-release oral
RxNorm normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release oral azathioprine 600 mg
Trial: 9048271
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral azathioprine 100 mg (control)
Trial: 8104966
Drug: Azelastine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 4 mg every 12 hours
Trial: 8104966
Drug: Azelastine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 8 mg every 12 hours
Trial: 8104966
Drug: Chlorpheniramine 12
RxNorm normalized name: Chlorpheniramine 12 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 12 mg every 12 hours
Trial: 8104966
Drug: Azelastine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (both doses)
Trial: 3535933
Drug: L-PAM plus
RxNorm normalized name: L-PAM
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-PAM plus 5-FU (PF)
Trial: 3535933
Drug: Nuclear grade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuclear grade in combination with either or both of the receptors
Trial: 30063470
Drug: Alemtuzumab as
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab as a conditioning agent
Trial: 27334138
Drug: n-3 LCPUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 LCPUFAs (722 mg DHA)
Trial: 27334138
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2000 IU) + n-3 LCPUFAs (722 mg DHA)
Trial: 22691894
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg for 6 days
Trial: 22691894
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg for 3 days after 4 mg for 3 days
Trial: 22691894
Drug: Alprazolam 1
RxNorm normalized name: alprazolam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1 mg on day 6
Trial: 18842795
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg as sulfate) and micronutrients 5 d/wk for 10 wk
Trial: 12192466
Drug: Intravenous citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous citalopram
Trial: 8540873
Drug: salbutamol 1
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 1 mg in 2 mL saline via jet nebuliser
Trial: 7148373
Drug: Incentive spirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive spirometry combined with chest physical therapy
Trial: 7148373
Drug: Chest physical
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest physical therapy alone
Trial: 25039260
Drug: Eight self-administered
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight self-administered weekly treatments with an 810-nm home-use laser at 5.0-6.4 J cm(‐2)
Trial: 25039260
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (zero treatments)
Trial: 23432535
Drug: Diltiazem supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem supplement
Trial: 23432535
Drug: Routine doses
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine doses of tacrolimus (Control)
Trial: 23432535
Drug: CYP3A5 polymorphism-guided
RxNorm normalized name: ANGELICA POLYMORPHA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A5 polymorphism-guided dosing equation
Trial: 21226883
Drug: Smoking reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking reduction counselling plus free nicotine replacement therapy (NRT)
Trial: 15625361
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor scintigraphy (SRS)
Trial: 9727686
Drug: Conversion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversion therapy (amiodarone for restoration and maintenance of sinus rhythm)
Trial: 9727686
Drug: Control of
RxNorm normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of ventricular rate only (diltiazem as primary therapy)
Trial: 8535958
Drug: 0.3% ofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% ofloxacin ophthalmic ointment
Trial: 8535958
Drug: 0.3% ofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% ofloxacin ophthalmic solution
Trial: 2403734
Drug: Low-dose sotalol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sotalol (160 mg administered twice daily)
Trial: 2403734
Drug: High-dose sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sotalol (320 mg administered twice daily)
Trial: 721790
Drug: Doxepin (112.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (112.7 mg/day)
Trial: 721790
Drug: Imipramine (116.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (116.7 mg/day)
Trial: 17392726
Drug: Methylnaltrexone 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone 0.3 mg/kg
Trial: 17216322
Drug: High spinal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High spinal anesthesia (2.7 ml of 0.5% hyperbaric bupivacaine)
Trial: 17216322
Drug: Low spinal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low spinal anesthesia (1.5 ml of 0.5% hyperbaric bupivacaine)
Trial: 31091508
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg)
Trial: 15577367
Drug: Bupivacaine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (150 mg)
Trial: 15577367
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg) and Bupivacaine (150 mg)
Trial: 9235679
Drug: Thromboprophylaxis (dextran‐70,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboprophylaxis (dextran‐70, low molecular weight heparin, and graded elastic stockings) during the first week after operation
Trial: 28763548
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (0.6-0.8 mg/kg/d; maximum 48 mg/d) for 2 months, followed by weaning over 4 to 6 months.
Trial: 25618178
Drug: Ovarian hyperstimulation
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian hyperstimulation with FSH + insemination + metformin
Trial: 14659529
Drug: Baseline psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline psychological measures during drug-free period
Trial: 10759689
Drug: Reviparin (s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reviparin (s.c. injection of 6300 anti-Xa units)
Trial: 10759689
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA 300 mg o.d. from day 1-5)
Trial: 10759689
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of reviparin and ASA
Trial: 10759689
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA 300 mg)
Trial: 10759689
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with ASA and reviparin
Trial: 20671623
Drug: S-adenosyl-L-methionine (SAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAM)
Trial: 30635887
Drug: Daily single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily single-dose triple therapy (esomeprazole 40 mg, tinidazole 1 g, levofloxacin 500 mg once-daily for 14 days)
Trial: 30635887
Drug: Conventional triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional triple therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg twice-daily for 14 days)
Trial: 30635887
Drug: Daily single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily single-dose triple therapy
Trial: 30635887
Drug: Conventional triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional triple therapy
Trial: 27233377
Drug: Continuous alternating
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous alternating therapy (CAT) with inhaled aztreonam (AZLI) and tobramycin inhalation solution (TIS)
Trial: 19968808
Drug: Remifentanil bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil bolus dose (3.1 mcg x kg(‐1) for group I, 3.7 mcg x kg(‐1) for group II, 3.0 mcg x kg(‐1) for group III)
Trial: 19968808
Drug: Remifentanil bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil bolus dose (3.1-3.7 mcg x kg(‐1))
Trial: 1614047
Drug: 1.36% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.36% glucose solution
Trial: 11920355
Drug: 2.27% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.27% glucose solution
Trial: 1614047
Drug: 3.86% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.86% glucose solution
Trial: 1614047
Drug: All glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All glucose solutions (1.36%, 2.27%, 3.86%)
Trial: 29112514
Drug: Intravenous cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cold saline (CS) (4°C)
Trial: 29112514
Drug: Intravenous room
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous room temperature saline (RS) (22°C)
Trial: 24265104
Drug: Cortisol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (20 mg) administered 1 hr before therapy sessions
Trial: 24265104
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 1 hr before therapy sessions
Trial: 22210231
Drug: Inhalation group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation group (sevoflurane-N2O)
Trial: 20563735
Drug: Topical tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tramadol (2 mg/kg diluted in 10 ml saline)
Trial: 20563735
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 ml saline)
Trial: 11339443
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.5-5 mg daily)
Trial: 11339443
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 (mean 0.5 mg daily)
Trial: 11339443
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (mean 16.5 mg daily)
Trial: 9347206
Drug: Oral triphasic
RxNorm normalized name: Tribasic Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triphasic contraceptive steroids (ethinyl estradiol and levonorgestrel)
Trial: 8137343
Drug: Chronic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic low dose etoposide administration (21 days)
Trial: 8137343
Drug: Frequent weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Frequent weekly or twice weekly administration of larger intravenous doses
Trial: 8137343
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of active intracellular drug concentrations
Trial: 3533811
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms L‐triiodothyronine
Trial: 30572991
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (1,500-2,000 IU daily)
Trial: 30572991
Drug: Non-intervention (Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intervention (Insulin treatment only)
Trial: 26954945
Drug: Fractionated coconut
RxNorm normalized name: Fractionated coconut oil
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated coconut oil 1.0 mL infused in the uterus on Day 10 (Group 1; n = 5)
Trial: 26954945
Drug: Fractionated coconut
RxNorm normalized name: Fractionated coconut oil
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated coconut oil 0.5 mL infused in the uterus on Day 10 (Group 2; n = 5)
Trial: 23252201
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of cefoxitin
Trial: 23252201
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of vitamin B complex intravenously
Trial: 19927027
Drug: 35% protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% protein (approximately 2.3 g x kg(‐1))
Trial: 19927027
Drug: 15% protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% protein (approximately 1.0 g x kg(‐1))
Trial: 18700714
Drug: Abhay M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abhay M vaccine
Trial: 18700714
Drug: M-Vac vaccine
RxNorm normalized name: M-2698
DrugBank: M-2698 (DB15431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-Vac vaccine
Trial: 10392981
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg acetylsalicylic acid daily
Trial: 10392981
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg acetylsalicylic acid daily
Trial: 10392981
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg acetylsalicylic acid daily
Trial: 10392981
Drug: 1300 mg
RxNorm normalized name: gelatin 1300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1300 mg acetylsalicylic acid daily
Trial: 10392981
Drug: Efficacy analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy analysis excluding patients taking 650 mg or more acetylsalicylic acid
Trial: 2066454
Drug: Adinazolam (60-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam (60-90 mg/day)
Trial: 2066454
Drug: Amitriptyline (150-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (150-225 mg/day)
Trial: 2066454
Drug: Diazepam (30-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (30-45 mg/day)
Trial: 28122361
Drug: Non-antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antiviral therapy
Trial: 26406981
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing cinnamon, chromium and carnosine (1.2 g/day)
Trial: 21269484
Drug: EPO therapy
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO therapy (5,000 IU subcutaneously at 48 h and 72 h after acute IS)
Trial: 21269484
Drug: EPO therapy
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO therapy (group 1)
Trial: 10395851
Drug: Atovaquone 750
RxNorm normalized name: ATOVAQUONE 750MG/5ML SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone 750 mg once a day
Trial: 10395851
Drug: Atovaquone 1500
RxNorm normalized name: ATOVAQUONE 1500 mg in 10 mL ORAL SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone 1500 mg once a day
Trial: 10395851
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine 300 mg once a month
Trial: 8847035
Drug: Octreotide 100
RxNorm normalized name: 1 ML octreotide 100 MCG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 100 mcg bolus intravenously followed by 25 mcg/h intravenously for 1.4 +/- 0.6 days
Trial: 8847035
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg intravenously every 12 h
Trial: 6896575
Drug: Isaxonine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isaxonine (4 capsules of 375 mg daily)
Trial: 6896575
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 capsules filled with lactose)
Trial: 27606613
Drug: 1500 ml
RxNorm normalized name: Bag/Pump Set 1500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 ml of oral rehydration solution (rehydration group)
Trial: 25963302
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pemirolast
Trial: 25963302
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg pemirolast
Trial: 25963302
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pemirolast
Trial: 17984344
Drug: Human and
RxNorm normalized name: cultured skin substitute,human and bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human and bovine praziquantel treatment
Trial: 17984344
Drug: Human praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human praziquantel treatment only
Trial: 15119493
Drug: Benzodiazepine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine treatment program
Trial: 15119493
Drug: Observation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation with CIWA-Ar administered every eight hours for 48 hours
Trial: 8178407
Drug: BCG Connaught
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG Connaught 120 mg
Trial: 2906556
Drug: L-tyrosine 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tyrosine 50, 250 and 500 mg kg-1
Trial: 2906556
Drug: L-tyrosine 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tyrosine 250 and 500 mg kg-1 with idazoxan (0.1 mg kg-1 i.v.)
Trial: 2906556
Drug: Idazoxan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (0.1 mg kg-1 i.v.)
Trial: 29921320
Drug: Navoximod (GDC-0919)
RxNorm normalized name: calcium carbonate
DrugBank: Navoximod (DB15439)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Navoximod (GDC-0919) administered at doses of 50-800 mg BID on a 21/28 day schedule and 600 mg on a 28/28 day schedule